AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OBIO
  4. [Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) director John Prosper Mack received two equity awards on June 24, 2025:

  • 12,422 Restricted Stock Units (RSUs) with a $0 exercise price
  • 36,797 Stock Options with an exercise price of $3.22 per share and expiration date of June 24, 2035

Both awards vest in a single installment at the earlier of: (1) one-year anniversary of grant date or (2) the 2026 Annual Meeting of Stockholders, subject to continued service. Following these transactions, Mack directly owns 25,286 shares of common stock and 36,797 stock options. This compensation structure aligns the director's interests with shareholders through both full-value shares and appreciation-only options.

Il direttore di Orchestra BioMed Holdings (OBIO), John Prosper Mack, ha ricevuto due premi in azioni il 24 giugno 2025:

  • 12.422 Unit脿 di Azioni Vincolate (RSU) con prezzo di esercizio pari a $0
  • 36.797 Opzioni su Azioni con un prezzo di esercizio di $3,22 per azione e scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al primo tra: (1) il primo anniversario della data di assegnazione o (2) l'Assemblea Annuale degli Azionisti del 2026, subordinatamente al mantenimento del servizio. A seguito di queste operazioni, Mack possiede direttamente 25.286 azioni ordinarie e 36.797 opzioni su azioni. Questa struttura retributiva allinea gli interessi del direttore con quelli degli azionisti attraverso azioni a valore pieno e opzioni basate solo sull'apprezzamento.

El director de Orchestra BioMed Holdings (OBIO), John Prosper Mack, recibi贸 dos premios en acciones el 24 de junio de 2025:

  • 12,422 Unidades Restringidas de Acciones (RSU) con un precio de ejercicio de $0
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n y fecha de vencimiento el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al primero de: (1) el aniversario de un a帽o desde la fecha de concesi贸n o (2) la Junta Anual de Accionistas de 2026, sujeto a la continuidad del servicio. Tras estas transacciones, Mack posee directamente 25,286 acciones comunes y 36,797 opciones sobre acciones. Esta estructura de compensaci贸n alinea los intereses del director con los de los accionistas mediante acciones de valor total y opciones solo de apreciaci贸n.

Orchestra BioMed Holdings (OBIO) 鞚挫偓 John Prosper Mack电� 2025雲� 6鞗� 24鞚�鞐� 霊� 臧�歆� 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU), 頄夓偓 臧�瓴� $0
  • 36,797 欤检嫕 鞓奠厴, 欤茧嫻 頄夓偓 臧�瓴� $3.22, 毵岆鞚� 2035雲� 6鞗� 24鞚�

霊� 氤挫儊 氇憪 (1) 攵�鞐澕搿滊秬韯� 1欤茧厔 霕惖鐢 (2) 2026雲� 欤检＜ 齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 攵勴暊搿� 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝鞚� 鞝侅毄霅╇媹雼�. 鞚� 瓯半灅 頉� Mack鞚� 氤错喌欤� 25,286欤检檧 欤检嫕 鞓奠厴 36,797欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅╇媹雼�. 鞚� 氤挫儊 甑“电� 鞝� 臧�旃� 欤检嫕瓿� 臧�旃� 靸侅姽順� 鞓奠厴鞚� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

Le directeur d'Orchestra BioMed Holdings (OBIO), John Prosper Mack, a re莽u deux attributions d'actions le 24 juin 2025 :

  • 12 422 unit茅s d'actions restreintes (RSU) avec un prix d'exercice de 0 $
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action et une date d'expiration au 24 juin 2035

Les deux attributions seront acquises en une seule tranche 脿 la premi猫re 茅ch茅ance entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assembl茅e annuelle des actionnaires de 2026, sous r茅serve de la poursuite du service. Apr猫s ces op茅rations, Mack d茅tient directement 25 286 actions ordinaires et 36 797 options d'achat. Cette structure de r茅mun茅ration aligne les int茅r锚ts du directeur avec ceux des actionnaires via des actions pleine valeur et des options 脿 valeur d'appr茅ciation uniquement.

Der Direktor von Orchestra BioMed Holdings (OBIO), John Prosper Mack, erhielt am 24. Juni 2025 zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie und Ablaufdatum am 24. Juni 2035

Beide Zuteilungen werden in einer einzigen Tranche f盲llig, entweder zum (1) einj盲hrigen Jahrestag des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich der fortgesetzten Dienstzeit. Nach diesen Transaktionen besitzt Mack direkt 25.286 Stammaktien und 36.797 Aktienoptionen. Diese Verg眉tungsstruktur richtet die Interessen des Direktors durch vollwertige Aktien und nur wertsteigernde Optionen an denen der Aktion盲re aus.

Positive
  • None.
Negative
  • None.

Il direttore di Orchestra BioMed Holdings (OBIO), John Prosper Mack, ha ricevuto due premi in azioni il 24 giugno 2025:

  • 12.422 Unit脿 di Azioni Vincolate (RSU) con prezzo di esercizio pari a $0
  • 36.797 Opzioni su Azioni con un prezzo di esercizio di $3,22 per azione e scadenza il 24 giugno 2035

Entrambi i premi maturano in un'unica tranche al primo tra: (1) il primo anniversario della data di assegnazione o (2) l'Assemblea Annuale degli Azionisti del 2026, subordinatamente al mantenimento del servizio. A seguito di queste operazioni, Mack possiede direttamente 25.286 azioni ordinarie e 36.797 opzioni su azioni. Questa struttura retributiva allinea gli interessi del direttore con quelli degli azionisti attraverso azioni a valore pieno e opzioni basate solo sull'apprezzamento.

El director de Orchestra BioMed Holdings (OBIO), John Prosper Mack, recibi贸 dos premios en acciones el 24 de junio de 2025:

  • 12,422 Unidades Restringidas de Acciones (RSU) con un precio de ejercicio de $0
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n y fecha de vencimiento el 24 de junio de 2035

Ambos premios se consolidan en un solo pago al primero de: (1) el aniversario de un a帽o desde la fecha de concesi贸n o (2) la Junta Anual de Accionistas de 2026, sujeto a la continuidad del servicio. Tras estas transacciones, Mack posee directamente 25,286 acciones comunes y 36,797 opciones sobre acciones. Esta estructura de compensaci贸n alinea los intereses del director con los de los accionistas mediante acciones de valor total y opciones solo de apreciaci贸n.

Orchestra BioMed Holdings (OBIO) 鞚挫偓 John Prosper Mack电� 2025雲� 6鞗� 24鞚�鞐� 霊� 臧�歆� 欤检嫕 氤挫儊鞚� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU), 頄夓偓 臧�瓴� $0
  • 36,797 欤检嫕 鞓奠厴, 欤茧嫻 頄夓偓 臧�瓴� $3.22, 毵岆鞚� 2035雲� 6鞗� 24鞚�

霊� 氤挫儊 氇憪 (1) 攵�鞐澕搿滊秬韯� 1欤茧厔 霕惖鐢 (2) 2026雲� 欤检＜ 齑濏殞 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 攵勴暊搿� 氩犾姢韺呺悩氅�, 瓿勳啀 攴茧 臁瓣贝鞚� 鞝侅毄霅╇媹雼�. 鞚� 瓯半灅 頉� Mack鞚� 氤错喌欤� 25,286欤检檧 欤检嫕 鞓奠厴 36,797欤茧ゼ 歆侅爲 氤挫湢頃橁矊 霅╇媹雼�. 鞚� 氤挫儊 甑“电� 鞝� 臧�旃� 欤检嫕瓿� 臧�旃� 靸侅姽順� 鞓奠厴鞚� 韱淀暣 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

Le directeur d'Orchestra BioMed Holdings (OBIO), John Prosper Mack, a re莽u deux attributions d'actions le 24 juin 2025 :

  • 12 422 unit茅s d'actions restreintes (RSU) avec un prix d'exercice de 0 $
  • 36 797 options d'achat d'actions avec un prix d'exercice de 3,22 $ par action et une date d'expiration au 24 juin 2035

Les deux attributions seront acquises en une seule tranche 脿 la premi猫re 茅ch茅ance entre : (1) le premier anniversaire de la date d'attribution ou (2) l'assembl茅e annuelle des actionnaires de 2026, sous r茅serve de la poursuite du service. Apr猫s ces op茅rations, Mack d茅tient directement 25 286 actions ordinaires et 36 797 options d'achat. Cette structure de r茅mun茅ration aligne les int茅r锚ts du directeur avec ceux des actionnaires via des actions pleine valeur et des options 脿 valeur d'appr茅ciation uniquement.

Der Direktor von Orchestra BioMed Holdings (OBIO), John Prosper Mack, erhielt am 24. Juni 2025 zwei Aktienzuteilungen:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie und Ablaufdatum am 24. Juni 2035

Beide Zuteilungen werden in einer einzigen Tranche f盲llig, entweder zum (1) einj盲hrigen Jahrestag des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026, vorbehaltlich der fortgesetzten Dienstzeit. Nach diesen Transaktionen besitzt Mack direkt 25.286 Stammaktien und 36.797 Aktienoptionen. Diese Verg眉tungsstruktur richtet die Interessen des Direktors durch vollwertige Aktien und nur wertsteigernde Optionen an denen der Aktion盲re aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mack John Prosper
(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
(Street)
NEW HOPE PA 18938
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 25,286 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at OBIO on June 24, 2025?

Director John Prosper Mack received two equity awards: 12,422 restricted stock units (RSUs) and 36,797 stock options with an exercise price of $3.22. The RSUs represent the right to receive OBIO common stock, while the stock options give the right to buy shares.

What is the vesting schedule for OBIO director John Mack's June 2025 stock awards?

Both the RSUs and stock options will vest in one installment on the earlier of: (1) the one-year anniversary of the June 24, 2025 grant date, or (2) the date of OBIO's 2026 Annual Meeting of Stockholders, subject to continuous service.

How many OBIO shares does John Mack own after the June 2025 transaction?

Following the transaction, John Mack directly owns 25,286 shares of OBIO common stock. Additionally, he holds 36,797 unvested stock options and 12,422 unvested RSUs that will convert to common shares upon vesting.

What is the exercise price of OBIO stock options granted to director John Mack?

The stock options were granted with an exercise price of $3.22 per share and have an expiration date of June 24, 2035, ten years from the grant date.
Stock OBIO logo
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

#4473 Ranked by Market Cap
N/A Ranked by Dividends

OBIO Latest News

Aug 26, 2025
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Aug 14, 2025
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Aug 12, 2025
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Aug 8, 2025
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Aug 5, 2025
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

OBIO Latest SEC Filings

Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[10-Q] Orchestra BioMed Holdings, Inc. Quarterly Earnings Report

OBIO Stock Data

140.28M
39.91M
16.19%
34.98%
1.31%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE